Tech Company Financing Transactions
Cabrellis Pharmaceuticals Funding Round
Cabrellis Pharmaceuticals, operating out of San Diego, secured $27.5 million in investment from Domain Associates, Forward Ventures and Lilly Ventures.
Transaction Overview
Company Name
Announced On
8/7/2006
Transaction Type
Venture Equity
Amount
$27,500,000
Round
Series A
Investors
Proceeds Purpose
The funding will be used to advance the clinical development of Calsed", the Company's third-generation anthracycline currently in Phase II clinical testing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9393 Towne Centre Dr. 210
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
The Company's lead product, Calsed (amrubicin hydrochloride), a third generation anthracycline and the world's first totally synthetic anthracycline drug, is currently in Phase II clinical testing in the United States.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Estok
Browse more venture capital transactions:
Prev: 8/7/2006: Kazeon Systems venture capital transaction
Next: 8/8/2006: Interwise venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs